154 related articles for article (PubMed ID: 10471590)
1. Activities of new antimicrobial agents (trovafloxacin, moxifloxacin, sanfetrinem, and quinupristin-dalfopristin) against Bacteroides fragilis group: comparison with the activities of 14 other agents.
Betriu C; Gómez M; Palau ML; Sánchez A; Picazo JJ
Antimicrob Agents Chemother; 1999 Sep; 43(9):2320-2. PubMed ID: 10471590
[TBL] [Abstract][Full Text] [Related]
2. Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin and nonquinolones linozelid, quinupristin-dalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxacin-resistant and -susceptible Staphylococcus aureus strains.
Jones ME; Visser MR; Klootwijk M; Heisig P; Verhoef J; Schmitz FJ
Antimicrob Agents Chemother; 1999 Feb; 43(2):421-3. PubMed ID: 9925551
[TBL] [Abstract][Full Text] [Related]
3. In vitro activities of newer quinolones against bacteroides group organisms.
Snydman DR; Jacobus NV; McDermott LA; Ruthazer R; Goldstein E; Finegold S; Harrell L; Hecht DW; Jenkins S; Pierson C; Venezia R; Rihs J; Gorbach SL
Antimicrob Agents Chemother; 2002 Oct; 46(10):3276-9. PubMed ID: 12234859
[TBL] [Abstract][Full Text] [Related]
4. Comparative in-vitro activities of moxifloxacin, trovafloxacin, quinupristin/dalfopristin and linezolid against staphylococci.
von Eiff C; Peters G
J Antimicrob Chemother; 1999 Apr; 43(4):569-73. PubMed ID: 10350389
[TBL] [Abstract][Full Text] [Related]
5. Changing patterns of fluoroquinolone resistance among Bacteroides fragilis group organisms over a 6-year period (1997-2002).
Betriu C; Rodríguez-Avial I; Gómez M; Culebras E; Picazo JJ
Diagn Microbiol Infect Dis; 2005 Nov; 53(3):221-3. PubMed ID: 16243476
[TBL] [Abstract][Full Text] [Related]
6. Comparative in vitro activities of linezolid, quinupristin-dalfopristin, moxifloxacin, and trovafloxacin against erythromycin-susceptible and -resistant streptococci.
Betriu C; Redondo M; Palau ML; Sánchez A; Gómez M; Culebras E; Boloix A; Picazo JJ
Antimicrob Agents Chemother; 2000 Jul; 44(7):1838-41. PubMed ID: 10858339
[TBL] [Abstract][Full Text] [Related]
7. Quinupristin-dalfopristin resistance among gram-positive bacteria in Taiwan.
Luh KT; Hsueh PR; Teng LJ; Pan HJ; Chen YC; Lu JJ; Wu JJ; Ho SW
Antimicrob Agents Chemother; 2000 Dec; 44(12):3374-80. PubMed ID: 11083643
[TBL] [Abstract][Full Text] [Related]
8. Activity of clinafloxacin, trovafloxacin, quinupristin/dalfopristin, and other antimicrobial agents versus Staphylococcus aureus isolates with reduced susceptibility to vancomycin.
Cohen MA; Huband MD
Diagn Microbiol Infect Dis; 1999 Jan; 33(1):43-6. PubMed ID: 9990475
[TBL] [Abstract][Full Text] [Related]
9. Comparative in vitro activity of penicillin G, levofloxacin, moxifloxacin, telithromycin, pristinamycin, quinupristin-dalfopristin and linezolid against ofloxacin-intermediate and -resistant Streptococcus pneumoniae.
Frédénucci I; Chomarat M; Bercion R; Carricajo A; Celard M; Croizé J; Delubac F; Fèvre D; Fuhrmann C; Helfre M; Letouzey MN; Lelièvre H; Mandjee A; Marthelet P; Meley R; Perrier-Gros-Claude JD; Ros A; Roure C; Smati S; Thierry J; Tous J
Clin Microbiol Infect; 2002 Oct; 8(10):680-3. PubMed ID: 12390289
[TBL] [Abstract][Full Text] [Related]
10. [Bactericidal activity of Trovafloxacin and Moxifloxacin against Gram-negative anaerobic bacilli].
Bosnea D; Stadoleanu C; Boswell FJ; Buiuc D
Rev Med Chir Soc Med Nat Iasi; 2000; 104(4):117-22. PubMed ID: 12089939
[TBL] [Abstract][Full Text] [Related]
11. Effect of pH on in vitro antimicrobial susceptibility of the Bacteroides fragilis group.
Falagas ME; McDermott L; Snydman DR
Antimicrob Agents Chemother; 1997 Sep; 41(9):2047-9. PubMed ID: 9303414
[TBL] [Abstract][Full Text] [Related]
12. Release of teichoic and lipoteichoic acids from 30 different strains of Streptococcus pneumoniae during exposure to ceftriaxone, meropenem, quinupristin/dalfopristin, rifampicin and trovafloxacin.
Heer C; Stuertz K; Reinert RR; Mäder M; Nau R
Infection; 2000; 28(1):13-20. PubMed ID: 10697785
[TBL] [Abstract][Full Text] [Related]
13. Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin, and telithromycin compared to their susceptibilities to reference macrolides, tetracyclines, and quinolones.
Kenny GE; Cartwright FD
Antimicrob Agents Chemother; 2001 Sep; 45(9):2604-8. PubMed ID: 11502536
[TBL] [Abstract][Full Text] [Related]
14. Comparative in vitro activities of ciprofloxacin, gemifloxacin, grepafloxacin, moxifloxacin, ofloxacin, sparfloxacin, trovafloxacin, and other antimicrobial agents against bloodstream isolates of gram-positive cocci.
Hardy D; Amsterdam D; Mandell LA; Rotstein C
Antimicrob Agents Chemother; 2000 Mar; 44(3):802-5. PubMed ID: 10681365
[TBL] [Abstract][Full Text] [Related]
15. Comparative activity of moxifloxacin in vitro against obligately anaerobic bacteria.
Ackermann G; Schaumann R; Pless B; Claros MC; Goldstein EJ; Rodloff AC
Eur J Clin Microbiol Infect Dis; 2000 Mar; 19(3):228-32. PubMed ID: 10795599
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of trovafloxacin against Bacteroides fragilis in mixed culture with either Escherichia coli or a vancomycin- resistant strain of Enterococcus faecium determined by an anaerobic time-kill technique.
Stearne LE; Kooi C; Goessens WH; Bakker-Woudenberg IA; Gyssens IC
Antimicrob Agents Chemother; 2001 Jan; 45(1):243-51. PubMed ID: 11120973
[TBL] [Abstract][Full Text] [Related]
17. Comparative activity of trovafloxacin and Bay 12-8039 against 452 clinical isolates of Streptococcus pneumoniae.
Weiss K; Laverdiere M; Restieri C
J Antimicrob Chemother; 1998 Oct; 42(4):523-5. PubMed ID: 9818753
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of quinupristin/dalfopristin and newer quinolones combined with gentamicin against resistant isolates of Enterococcus faecalis and Enterococcus faecium.
Giamarellos-Bourboulis EJ; Sambatakou H; Grecka P; Giamarellou H
Eur J Clin Microbiol Infect Dis; 1998 Sep; 17(9):657-61. PubMed ID: 9832270
[TBL] [Abstract][Full Text] [Related]
19. Differential release of lipoteichoic and teichoic acids from Streptococcus pneumoniae as a result of exposure to beta-lactam antibiotics, rifamycins, trovafloxacin, and quinupristin-dalfopristin.
Stuertz K; Schmidt H; Eiffert H; Schwartz P; Mäder M; Nau R
Antimicrob Agents Chemother; 1998 Feb; 42(2):277-81. PubMed ID: 9527772
[TBL] [Abstract][Full Text] [Related]
20. Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
Lee Y; Park Y; Kim MS; Yong D; Jeong SH; Lee K; Chong Y
Antimicrob Agents Chemother; 2010 Sep; 54(9):3993-7. PubMed ID: 20585132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
